For the Inventor, By the Inventor

Enter assignee name

Planegg, Germany

Morphosys Ag

USPTO Granted Patents = 88

CIPO Patents = 11

EPO Patents = 52

Trademarks = 30

Forward Citations = 1,036

Loading Chart...

Loading Chart...

117 inventors (with patents filed for the assignee):

Josef Prassler (12 out of 20 patents)

Michael Tesar (11 out of 15 patents)

Jan Endell (9 out of 11 patents)

4. Thomas Tiller (9 out of 10 patents)

5. Markus Enzelberger (8 out of 11 patents)

6. Peter Pack (8 out of 8 patents)

7. Stefanie Urlinger (7 out of 16 patents)

8. Stefan Steidl (7 out of 8 patents)

9. Yvonne Stark (7 out of 7 patents)

10. Achim Knappik (7 out of 8 patents)

11. Liming Ge (7 out of 7 patents)

12. Mark Winderlich (6 out of 7 patents)

13. Rainer Boxhammer (6 out of 8 patents)

14. Ute Jäger (6 out of 6 patents)

15. Elisabeth Thomassen-Wolf (5 out of 5 patents)

Core Competencies:

Therapeutic Antibodies

Humanized Antibodies

Antibody Libraries

Multiple Myeloma Treatment

IL-17C Antagonists

Anti-GM-CSF Antibodies

Peptide Libraries

Fusion Proteins

Anti-CD19 Antibodies

Rodent Combinatorial Libraries

Glycoprotein VI Targeting

M-CSF Antibodies

88 patents: Sort by Forward Citations

1. 12018072 - Antibodies specific for human complement C5A receptor (C5AR) (2024-06-25),

2. 11987621 - Antibodies for IL-17C (2024-05-21),

3. 11939395 - Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38 (2024-03-26),

4. 11702463 - Canine antibody libraries (2023-07-18),

5. 11618789 - Clinical assessment of M-protein response in multiple myeloma (2023-04-04),

6. 11591406 - Treatment for multiple myeloma (MM) (2023-02-28),

7. 11542329 - Antibodies targeting Glycoprotein VI (2023-01-03),

8. 11472880 - Humanized antibodies for CD3 (2022-10-18),

9. 11352620 - Peptide libraries (2022-06-07),

10. 11352423 - Anti-CD19 antibody formulations (2022-06-07),

11. 11254734 - Fab molecules with a rodent hinge region and a non-rodent CH1 region (2022-02-22),

12. 11224654 - Combinations and uses thereof (2022-01-18),

13. 11085038 - Polypeptide library (2021-08-10),

14. 11059902 - Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 (2021-07-13),

15. 11028165 - Nucleic acid encoding anti-GM-CSF antibodies (2021-06-08),

MorphoSys AG is a biopharmaceutical company that focuses on the research, development, and production of innovative therapeutic antibodies. With over 25 years of experience, the company has established itself as a leader in the field of antibody technology. MorphoSys AG leverages its proprietary technology platforms to discover and optimize antibodies for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Through collaborations and partnerships, the company brings its therapeutic antibodies to market, providing patients with new treatment options. For more information about MorphoSys AG and their innovative approaches to antibody therapy, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

88 Patents

#1 in Planegg

#687 in Germany

#8,413 in the World

Planegg, Germany

Morphosys Ag

Forward Citations = 1,036

117 inventors:

Josef Prassler (12 out of 20 patents)

Michael Tesar (11 out of 15 patents)

Jan Endell (9 out of 11 patents)

4. Thomas Tiller (9 out of 10 patents)

5. Markus Enzelberger (8 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…